Physician profile
Joshua T Stone
NPI 1700290814
$2,039.92
in general payments reported to CMS, 2019-2025
27 companies · $156 in 2025
The $156 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $41.65 · 2021: $11.78 · 2022: $11.86 · 2023: $1,178 · 2024: $223 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $814 · Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $814.46 |
| Food and Beverage | $742.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Peerless Surgical INC. | $738.86 | 2023-2024 | |
| Arthrex, INC. | $278.08 | 2023 | |
| Ferring Pharmaceuticals INC. | $162.18 | 2021-2025 | Euflexxa |
| Depuy Synthes Sales INC. | $138.29 | 2019-2025 | Orthovisc, Monovisc |
| Bioventus LLC | $86.54 | 2019-2024 | Exogen Ultrasound Bone Healing System, Durolane, Durolane |
| Electronic Waveform Lab, INC. | $85.31 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $68.59 | 2019 | |
| Pacira Therapeutics, INC. | $56.50 | 2019 | |
| Fidia Pharma USA INC. | $52.32 | 2019-2024 | Triluron, Hymovis, Hyalgan |
| Amgen INC. | $44.60 | 2019-2024 | Prolia, Evenity |
| Pacira Pharmaceuticals Incorporated | $35.11 | 2023-2025 | Zilretta, Iovera |
| Innovation Technologies INC | $27.82 | 2025 | Irrisept |
| Gilead Sciences, INC. | $26.94 | 2023 | |
| Janssen Pharmaceuticals, INC | $25.95 | 2019 | |
| Smith+Nephew, INC. | $20.82 | 2025 | Real Intelligence, Polarstem |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.92 | 2019 | |
| Lilly USA, LLC | $18.56 | 2025 | Zepbound, Mounjaro |
| Ethicon US, LLC | $18.55 | 2024 | Surgiflo Hemostatic Matrix, Evarrest, Vistaseal |
| Astellas Pharma US INC | $17.71 | 2019 | |
| Convatec INC. | $17.01 | 2025 | |
| Abbvie INC. | $16.73 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.46 | 2019 | |
| Vericel Corporation | $15.05 | 2020 | |
| Medtronic USA, INC. | $13.95 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.45 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.97 | 2019 | |
| Bsn Medical INC | $12.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.